{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:50:15Z","timestamp":1793364615486,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U2C-CA233262"],"award-info":[{"award-number":["U2C-CA233262"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54-CA225088"],"award-info":[{"award-number":["U54-CA225088"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00401-019-02029-5","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:07:17Z","timestamp":1559617637000},"page":"643-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":185,"title":["An update on the CNS manifestations of neurofibromatosis type 2"],"prefix":"10.1007","volume":"139","author":[{"given":"Shannon","family":"Coy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumana","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7528-9668","authenticated-orcid":false,"given":"Sandro","family":"Santagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"2029_CR1","first-page":"294","volume-title":"WHO classification of tumors of the central nervous system","author":"DN Louis","year":"2016","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumors of the central nervous system. IARC\/WHO, Lyon, pp 294\u2013303"},{"key":"2029_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0147-0272(82)80016-0","volume":"8","author":"VM Riccardi","year":"1982","unstructured":"Riccardi VM (1982) Neurofibromatosis: clinical heterogeneity. Curr Probl Cancer 8:1\u201334","journal-title":"Curr Probl Cancer"},{"issue":"3","key":"2029_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ajmg.a.38486","volume":"176","author":"M Ruggieri","year":"2018","unstructured":"Ruggieri M, Pratic\u00f2 AD, Caltabiano R, Polizzi A (2018) Early history of the different forms of neurofibromatosis from ancient Egypt to the British Empire and beyond: first descriptions, medical curiosities, misconceptions, landmarks, and the persons behind the syndromes. Am J Med Genet A. 176(3):515\u2013550. \nhttps:\/\/doi.org\/10.1002\/ajmg.a.38486","journal-title":"Am J Med Genet A."},{"key":"2029_CR4","volume-title":"Ueber die multiplen fibroma der haut und ihre beziehung zu den multiplen neuromen","author":"F Von Recklinghausen","year":"1882","unstructured":"Von Recklinghausen F (1882) Ueber die multiplen fibroma der haut und ihre beziehung zu den multiplen neuromen. A Hirschwald, Berlin"},{"key":"2029_CR5","first-page":"393","volume":"18","author":"JH Wishart","year":"1822","unstructured":"Wishart JH (1822) Case of tumours in the skull, dura mater, and brain. Edinb Med Surg J 18:393\u2013397","journal-title":"Edinb Med Surg J"},{"key":"2029_CR6","volume-title":"Tumors of the nervus acusticus and the syndrome of the cerebello-pontine angle","author":"H Cushing","year":"1917","unstructured":"Cushing H (1917) Tumors of the nervus acusticus and the syndrome of the cerebello-pontine angle. WB Saunders, Philadelphia"},{"key":"2029_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/archneurpsyc.1930.02220080050005","volume":"23","author":"WJ Gardner","year":"1930","unstructured":"Gardner WJ, Frazier CH (1930) Bilateral acoustic neurofibromas: a clinical study and field survey of a family of five generations with bilateral deafness in thirty eight members. Arch Neurol Psychiatry 23:266\u2013302","journal-title":"Arch Neurol Psychiatry"},{"key":"2029_CR8","volume-title":"A clinical pathological and genetic study of multiple neurofibromatosis","author":"FW Crowe","year":"1956","unstructured":"Crowe FW, Schull WJ, Neal JV (1956) A clinical pathological and genetic study of multiple neurofibromatosis. Charles C Thomas, Springfield"},{"key":"2029_CR9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0092-8674(87)90534-4","volume":"49","author":"BR Seizinger","year":"1987","unstructured":"Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, Chao MV et al (1987) Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 49:589\u2013594","journal-title":"Cell"},{"key":"2029_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/329246a0","volume":"329","author":"GA Rouleau","year":"1987","unstructured":"Rouleau GA, Wertelecki W, Haines JL, Hobbs WJ, Trofatter JA, Seizinger BR et al (1987) Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329:246\u2013248","journal-title":"Nature"},{"key":"2029_CR11","unstructured":"National Institutes of Health consensus development conference statement on neurofibromatosis (1987). In: National Institutes of Health consensus development conference statement, Jul 13\u201315, 1987, vol 6(12), pp 1\u20137"},{"issue":"11","key":"2029_CR12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","volume":"64","author":"M MacCollin","year":"2005","unstructured":"MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D et al (2005) Diagnostic criteria for schwannomatosis. Neurology 64(11):1838\u20131845","journal-title":"Neurology"},{"issue":"3","key":"2029_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","volume":"161A","author":"SR Plotkin","year":"2013","unstructured":"Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K et al (2013) Update from the 2011 international schwannomatosis workshop: from genetics to diagnostic criteria. Am J Med Genet A 161A(3):405\u2013416","journal-title":"Am J Med Genet A"},{"issue":"6","key":"2029_CR14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.ejhg.5200493","volume":"8","author":"S Tinschert","year":"2000","unstructured":"Tinschert S, Naumann I, Stegmann E, Buske A, Kaufmann D, Thiel G et al (2000) Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 8(6):455\u2013459","journal-title":"Eur J Hum Genet"},{"key":"2029_CR15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/bmj.1.3093.496","volume":"10","author":"A Feiling","year":"1920","unstructured":"Feiling A, Ward EA (1920) familial form of acoustic tumour. BMJ 10:496\u2013497","journal-title":"BMJ"},{"issue":"11","key":"2029_CR16","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59(11):1759\u20131765","journal-title":"Neurology"},{"key":"2029_CR17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K et al (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515\u2013521","journal-title":"Nature"},{"key":"2029_CR18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM et al (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791\u2013800","journal-title":"Cell"},{"key":"2029_CR19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/gepi.10238","volume":"24","author":"R Woods","year":"2003","unstructured":"Woods R, Friedman JM, Evans DG, Baser ME, Joe H (2003) Exploring the \u201ctwo-hit hypothesis\u201d in NF2: tests of two-hit and three-hit models of vestibular schwannoma development. Genet Epidemiol 24:265\u2013272","journal-title":"Genet Epidemiol"},{"issue":"10","key":"2029_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","volume":"54","author":"D Halliday","year":"2017","unstructured":"Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H et al (2017) Genetic severity Score predicts clinical phenotype in NF2. J Med Genet 54(10):657\u2013664. \nhttps:\/\/doi.org\/10.1136\/jmedgenet-2017-104519","journal-title":"J Med Genet"},{"key":"2029_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2005-837581","volume":"36","author":"M Ruggieri","year":"2005","unstructured":"Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O et al (2005) Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 36:21\u201334","journal-title":"Neuropediatrics"},{"key":"2029_CR22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/adc.81.6.496","volume":"81","author":"DGR Evans","year":"1999","unstructured":"Evans DGR, Birch JM, Ramsden RT (1999) Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 81:496\u2013499","journal-title":"Arch Dis Child"},{"key":"2029_CR23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/jmg.29.12.841","volume":"29","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D et al (1992) A genetic study of type 2 neurofibromatosis in the United Kingdom: I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 29:841\u2013846","journal-title":"J Med Genet"},{"key":"2029_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DGR Evans","year":"2005","unstructured":"Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93\u201397","journal-title":"Otol Neurotol"},{"issue":"4","key":"2029_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"19","author":"DG Evans","year":"2009","unstructured":"Evans DG (2009) Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 19(4):16. \nhttps:\/\/doi.org\/10.1186\/1750-1172-4-16","journal-title":"Orphanet J Rare Dis"},{"key":"2029_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jmg.40.2.109","volume":"40","author":"L Kluwe","year":"2003","unstructured":"Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE et al (2003) Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 40:109\u2013114","journal-title":"J Med Genet"},{"key":"2029_CR27","first-page":"727","volume":"63","author":"DGR Evans","year":"1998","unstructured":"Evans DGR, Wallace A, Trueman L, Wu C-L, Ramsden RT, Strachan T (1998) Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 63:727\u2013736","journal-title":"Am J Hum Genet"},{"issue":"7","key":"2029_CR28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jmg.2006.047753","volume":"44","author":"DG Evans","year":"2007","unstructured":"Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM et al (2007) Mosaicism in neurofibromatosis type 2: an update of risk based on uni\/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 44(7):424\u2013428","journal-title":"J Med Genet"},{"issue":"11","key":"2029_CR29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1177\/002215549904701113","volume":"47","author":"MA den Bakker","year":"1999","unstructured":"den Bakker MA, Vissers KJ, Molijn AC, Kros JM, Zwarthoff EC, van der Kwast TH (1999) Expression of the neurofibromatosis type 2 gene in human tissues. J Histochem Cytochem 47(11):1471\u20131480","journal-title":"J Histochem Cytochem"},{"issue":"8","key":"2029_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0968-0004(98)01237-7","volume":"23","author":"AH Chishti","year":"1998","unstructured":"Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H et al (1998) The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 23(8):281\u2013282","journal-title":"Trends Biochem Sci"},{"issue":"8","key":"2029_CR31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.189601","volume":"15","author":"H Morrison","year":"2001","unstructured":"Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA et al (2001) The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 15(8):968\u2013980","journal-title":"Genes Dev"},{"issue":"1","key":"2029_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ncb1339","volume":"8","author":"F Hamaratoglu","year":"2006","unstructured":"Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C et al (2006) The tumour-suppressor genes NF2\/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8(1):27\u201336","journal-title":"Nat Cell Biol"},{"issue":"1","key":"2029_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.devcel.2010.06.015","volume":"19","author":"N Zhang","year":"2010","unstructured":"Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J et al (2010) The Merlin\/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19(1):27\u201338. \nhttps:\/\/doi.org\/10.1016\/j.devcel.2010.06.015","journal-title":"Dev Cell"},{"issue":"5","key":"2029_CR34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tcb.2007.03.006","volume":"17","author":"T Okada","year":"2007","unstructured":"Okada T, You L, Giancotti FG (2007) Shedding light on Merlin\u2019s wizardry. Trends Cell Biol 17(5):222\u2013229","journal-title":"Trends Cell Biol"},{"issue":"1","key":"2029_CR35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","volume":"26","author":"W Li","year":"2014","unstructured":"Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D et al (2014) Merlin\/NF2 loss-driven tumorigenesis linked to CRL4 (DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26(1):48\u201360","journal-title":"Cancer Cell"},{"issue":"4","key":"2029_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L et al (2010) Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4 (DCAF1) in the nucleus. Cell 140(4):477\u2013490. \nhttps:\/\/doi.org\/10.1016\/j.cell.2010.01.029","journal-title":"Cell"},{"issue":"18","key":"2029_CR37","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","volume":"77","author":"DS Stepanova","year":"2017","unstructured":"Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO et al (2017) An essential role for the tumor-suppressor merlin in regulating fatty acid synthesis. Cancer Res 77(18):5026\u20135038","journal-title":"Cancer Res"},{"issue":"6","key":"2029_CR38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138920310791824011","volume":"11","author":"I Stamenkovic","year":"2010","unstructured":"Stamenkovic I, Yu Q (2010) Merlin, a \u201cmagic\u201d linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci 11(6):471\u2013484","journal-title":"Curr Protein Pept Sci"},{"issue":"16","key":"2029_CR39","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","volume":"588","author":"J Cooper","year":"2014","unstructured":"Cooper J, Giancotti FG (2014) Molecular insights into NF2\/Merlin tumor suppressor function. FEBS Lett. 588(16):2743\u20132752. \nhttps:\/\/doi.org\/10.1016\/j.febslet.2014.04.001","journal-title":"FEBS Lett."},{"key":"2029_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/wno.0000000000000675","author":"SL Painter","year":"2018","unstructured":"Painter SL, Sipkova Z, Emmanouil B, Halliday D, Parry A, Elston JS (2018) Neurofibromatosis type 2-related eye disease correlated with genetic severity type. J Neuroophthalmol. \nhttps:\/\/doi.org\/10.1097\/wno.0000000000000675","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"2029_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmg.2010.085241","volume":"48","author":"MJ Smith","year":"2011","unstructured":"Smith MJ, Higgs JE, Bowers NL, Halliday D, Paterson J, Gillespie J et al (2011) Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 48(4):261\u2013265. \nhttps:\/\/doi.org\/10.1136\/jmg.2010.085241","journal-title":"J Med Genet"},{"issue":"6","key":"2029_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jmedgenet-2014-102973","volume":"52","author":"DG Evans","year":"2015","unstructured":"Evans DG, Freeman S, Gokhale C, Wallace A, Lloyd SK, Axon P et al (2015) Manchester NF2 service. Bilateral vestibular schwannomas in older patients: NF2 or chance? J Med Genet 52(6):422\u2013424. \nhttps:\/\/doi.org\/10.1136\/jmedgenet-2014-102973","journal-title":"J Med Genet"},{"issue":"1","key":"2029_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","volume":"88","author":"MJ Smith","year":"2017","unstructured":"Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT et al (2017) Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 88(1):87\u201392. \nhttps:\/\/doi.org\/10.1212\/WNL.0000000000003418","journal-title":"Neurology"},{"key":"2029_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41436-018-0384-y","volume":"25","author":"DG Evans","year":"2018","unstructured":"Evans DG, King AT, Bowers NL, Tobi S, Wallace AJ et al (2018) Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing. Genet Med. 25:25. \nhttps:\/\/doi.org\/10.1038\/s41436-018-0384-y","journal-title":"Genet Med."},{"issue":"7 Suppl 1","key":"2029_CR45","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1212\/WNL.0000000000002932","volume":"87","author":"CO Hanemann","year":"2016","unstructured":"Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V et al (2016) Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology 87(7 Suppl 1):S40\u2013S48","journal-title":"Neurology"},{"issue":"4","key":"2029_CR46","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","volume":"52","author":"DM Parry","year":"1994","unstructured":"Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52(4):450\u2013461","journal-title":"Am J Med Genet"},{"issue":"8","key":"2029_CR47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jmedgenet-2015-103050","volume":"52","author":"SM Stivaros","year":"2015","unstructured":"Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A et al (2015) Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet 52(8):557\u2013562","journal-title":"J Med Genet"},{"issue":"2","key":"2029_CR48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000331394","volume":"17","author":"C Roosli","year":"2012","unstructured":"Roosli C, Linthicum FH Jr, Cureoglu S, Merchant SN (2012) What is the site of origin of cochleovestibular schwannomas? Audiol Neurootol. 17(2):121\u2013125","journal-title":"Audiol Neurootol."},{"key":"2029_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"1","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD et al (2015) A murine model of Neurofibromatosis Type 2 that accurately phenocopies human schwannoma formation. Hum Mol Genet 1:1\u20138","journal-title":"Hum Mol Genet"},{"issue":"5","key":"2029_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/MAO.0000000000000272","volume":"35","author":"A Maniakas","year":"2014","unstructured":"Maniakas A, Saliba I (2014) Neurofibromatosis type 2 vestibular schwannoma treatment: a review of the literature, trends, and outcomes. Otol Neurotol 35(5):889\u2013894. \nhttps:\/\/doi.org\/10.1097\/MAO.0000000000000272","journal-title":"Otol Neurotol"},{"issue":"8","key":"2029_CR51","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/MAO.0b013e31815a8411","volume":"28","author":"LM Fisher","year":"2007","unstructured":"Fisher LM, Doherty JK, Lev MH, Slattery WH III (2007) Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2. Otol Neurotol. 28(8):1083\u20131090","journal-title":"Otol Neurotol."},{"key":"2029_CR52","first-page":"603","volume":"84","author":"DGR Evans","year":"1992","unstructured":"Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V et al (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603\u2013618","journal-title":"Q J Med"},{"issue":"5","key":"2029_CR53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.humpath.2007.10.029","volume":"39","author":"JC Berg","year":"2008","unstructured":"Berg JC, Scheithauer BW, Spinner RJ, Allen CM, Koutlas IG (2008) Plexiform schwannoma: a clinicopathologic overview with emphasis on the head and neck region. Hum Pathol 39(5):633\u2013640","journal-title":"Hum Pathol"},{"issue":"4","key":"2029_CR54","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/neuonc\/nou317","volume":"17","author":"R Dewan","year":"2015","unstructured":"Dewan R, Pemov A, Kim HJ, Morgan KL, Vasquez RA, Chittiboina P et al (2015) Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 17(4):566\u2013573. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nou317","journal-title":"Neuro Oncol"},{"issue":"4","key":"2029_CR55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0090-3019(96)00487-9","volume":"48","author":"Y Hamada","year":"1997","unstructured":"Hamada Y, Iwaki T, Fukui M, Tateishi J (1997) A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas. Surg Neurol 48(4):395\u2013400","journal-title":"Surg Neurol"},{"issue":"3","key":"2029_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/bpa.12125","volume":"24","author":"DA Hilton","year":"2014","unstructured":"Hilton DA, Hanemann CO (2014) Schwannomas and their pathogenesis. Brain Pathol 24(3):205\u2013220. \nhttps:\/\/doi.org\/10.1111\/bpa.12125","journal-title":"Brain Pathol"},{"issue":"12","key":"2029_CR57","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/00005072-199812000-00008","volume":"57","author":"AO Stemmer-Rachamimov","year":"1998","unstructured":"Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella JF et al (1998) Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol 57(12):1164\u20131167","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"2029_CR58","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","volume":"131","author":"M R\u00f6hrich","year":"2016","unstructured":"R\u00f6hrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A et al (2016) Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol 131(6):877\u2013887","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2029_CR59","doi-asserted-by":"publisher","first-page":"W646","DOI":"10.2214\/AJR.12.8577","volume":"200","author":"NA Koontz","year":"2013","unstructured":"Koontz NA, Wiens AL, Agarwal A, Hingtgen CM, Emerson RE, Mosier KM (2013) Schwannomatosis: the overlooked neurofibromatosis? AJR Am J Roentgenol 200(6):W646\u2013W653. \nhttps:\/\/doi.org\/10.2214\/AJR.12.8577","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"2029_CR60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/neuros\/nyx368","volume":"83","author":"AT King","year":"2018","unstructured":"King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON (2018) Malignant peripheral nerve sheath tumors are not a feature of neurofibromatosis type 2 in the unirradiated patient. Neurosurgery 83(1):38\u201342","journal-title":"Neurosurgery"},{"issue":"4","key":"2029_CR61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, Halpin C, Padera TP, Tyrrell A et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367","journal-title":"N Engl J Med"},{"issue":"47","key":"2029_CR62","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S et al (2015) Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci USA 112(47):14676\u201314681. \nhttps:\/\/doi.org\/10.1073\/pnas.1512570112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2029_CR63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart A, Gaillard V, Baroncini M, Andr\u00e9 N, Vannier JP, Vinchon M et al (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124(2):229\u2013236","journal-title":"J Neurooncol"},{"issue":"6","key":"2029_CR64","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2559.2009.03440.x","volume":"55","author":"DA Hilton","year":"2009","unstructured":"Hilton DA, Ristic N, Hanemann CO (2009) Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 55(6):744\u2013749. \nhttps:\/\/doi.org\/10.1111\/j.1365-2559.2009.03440.x","journal-title":"Histopathology"},{"issue":"2","key":"2029_CR65","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","volume":"67","author":"H Morrison","year":"2007","unstructured":"Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, Herrlich P (2007) Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67(2):520\u2013527","journal-title":"Cancer Res"},{"issue":"11","key":"2029_CR66","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/glia.22391","volume":"60","author":"S Ammoun","year":"2012","unstructured":"Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C, Hanemann CO (2012) The role of insulin-like growth factors signaling in merlin deficient human schwannomas. Glia 60(11):1721\u20131733","journal-title":"Glia"},{"key":"2029_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz002","author":"MA Fuse","year":"2019","unstructured":"Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK et al (2019) Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveal differences in efficacy and drug resistance development. Neuro Oncol. \nhttps:\/\/doi.org\/10.1093\/neuonc\/noz002","journal-title":"Neuro Oncol"},{"issue":"7","key":"2029_CR68","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/neuonc\/nor056","volume":"13","author":"S Ammoun","year":"2011","unstructured":"Ammoun S, Schmid MC, Triner J, Manley P, Hanemann CO (2011) Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol. 13(7):759\u2013766. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nor056","journal-title":"Neuro Oncol."},{"issue":"2","key":"2029_CR69","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D et al (2015) Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 122(2):313\u2013320. \nhttps:\/\/doi.org\/10.1007\/s11060-014-1710-0","journal-title":"J Neurooncol"},{"issue":"4","key":"2029_CR70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/neuonc\/not242","volume":"16","author":"M Giovannini","year":"2014","unstructured":"Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R et al (2014) mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol. 16(4):493\u2013504. \nhttps:\/\/doi.org\/10.1093\/neuonc\/not242","journal-title":"Neuro Oncol."},{"issue":"11","key":"2029_CR71","doi-asserted-by":"publisher","first-page":"9940","DOI":"10.18632\/oncotarget.24119","volume":"9","author":"M Breun","year":"2018","unstructured":"Breun M, Schwerdtfeger A, Martellotta DD, Kessler AF, Perez JM, Monoranu CM et al (2018) CXCR72: a new player in vestibular schwannoma pathogenesis. Oncotarget 9(11):9940\u20139950. \nhttps:\/\/doi.org\/10.18632\/oncotarget.24119","journal-title":"Oncotarget"},{"issue":"9","key":"2029_CR72","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L et al (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci USA 115(9):E2077\u2013E2084. \nhttps:\/\/doi.org\/10.1073\/pnas.1719966115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2029_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","volume":"138","author":"S Wang","year":"2018","unstructured":"Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M et al (2018) Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol 138(1):183\u2013190. \nhttps:\/\/doi.org\/10.1007\/s11060-018-2788-6","journal-title":"J Neurooncol"},{"issue":"1","key":"2029_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11060-017-2567-9","volume":"135","author":"I Paldor","year":"2017","unstructured":"Paldor I, Abbadi S, Bonne N, Ye X, Rodriguez FJ, Rowshanshad D et al (2017) The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma. J Neurooncol 135(1):47\u201356. \nhttps:\/\/doi.org\/10.1007\/s11060-017-2567-9","journal-title":"J Neurooncol"},{"issue":"11","key":"2029_CR75","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/ng.3688","volume":"48","author":"S Agnihotri","year":"2016","unstructured":"Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G et al (2016) The genomic landscape of schwannoma. Nat Genet 48(11):1339\u20131348","journal-title":"Nat Genet"},{"issue":"4","key":"2029_CR76","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2214\/ajr.165.4.7676998","volume":"165","author":"VF Mautner","year":"1995","unstructured":"Mautner VF, Tatagiba M, Lindenau M, F\u00fcnsterer C, Pulst SM, Baser ME et al (1995) Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol 165(4):951\u2013955","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"2029_CR77","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11060-010-0339-x","volume":"99","author":"S Goutagny","year":"2010","unstructured":"Goutagny S, Kalamarides M (2010) Meningiomas and neurofibromatosis. J Neurooncol 99(3):341\u2013347. \nhttps:\/\/doi.org\/10.1007\/s11060-010-0339-x","journal-title":"J Neurooncol"},{"issue":"6123","key":"2029_CR78","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077\u20131080. \nhttps:\/\/doi.org\/10.1126\/science.1233009","journal-title":"Science"},{"issue":"4","key":"2029_CR79","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","volume":"71","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT et al (2002) Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71(4):715\u2013723","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2029_CR80","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/neuonc\/nov316","volume":"18","author":"M Abedalthagafi","year":"2016","unstructured":"Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK et al (2016) Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 18(5):649\u2013655. \nhttps:\/\/doi.org\/10.1093\/neuonc\/nov316","journal-title":"Neuro Oncol"},{"issue":"10","key":"2029_CR81","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jnen\/60.10.994","volume":"60","author":"A Perry","year":"2001","unstructured":"Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L et al (2001) Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 60(10):994\u20131003","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2029_CR82","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ajhg.2012.07.015","volume":"91","author":"M Aavikko","year":"2012","unstructured":"Aavikko M, Li SP, Saarinen S, Alhopuro P, Kaasinen E, Morgunova E et al (2012) Loss of SUFU function in familial multiple meningioma. Am J Hum Genet 91(3):520\u2013526. \nhttps:\/\/doi.org\/10.1016\/j.ajhg.2012.07.015","journal-title":"Am J Hum Genet"},{"issue":"4","key":"2029_CR83","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/path.4427","volume":"234","author":"MJ Smith","year":"2014","unstructured":"Smith MJ, Wallace AJ, Bennett C, Hasselblatt M, Elert-Dobkowska E, Evans LT et al (2014) Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 234(4):436\u2013440. \nhttps:\/\/doi.org\/10.1002\/path.4427","journal-title":"J Pathol"},{"issue":"1","key":"2029_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-011-0300-y","volume":"13","author":"P van den Munckhof","year":"2012","unstructured":"van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ (2012) Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13(1):1\u20137. \nhttps:\/\/doi.org\/10.1007\/s10048-011-0300-y","journal-title":"Neurogenetics"},{"issue":"1","key":"2029_CR85","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12885-017-3127-6","volume":"17","author":"R Dewan","year":"2017","unstructured":"Dewan R, Pemov A, Dutra AS, Pak ED, Edwards NA, Ray-Chaudhury A et al (2017) First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation. BMC Cancer 17(1):127","journal-title":"BMC Cancer"},{"issue":"15","key":"2029_CR86","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO et al (2009) NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 29(15):4250\u20134261. \nhttps:\/\/doi.org\/10.1128\/MCB.01581-08","journal-title":"Mol Cell Biol"},{"issue":"2","key":"2029_CR87","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","volume":"133","author":"S Goutagny","year":"2017","unstructured":"Goutagny S, Giovannini M, Kalamarides M (2017) A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J Neurooncol 133(2):443\u2013445. \nhttps:\/\/doi.org\/10.1007\/s11060-017-2447-3","journal-title":"J Neurooncol"},{"issue":"9","key":"2029_CR88","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","volume":"20","author":"SP Angus","year":"2018","unstructured":"Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L et al (2018) EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol 20(9):1185\u20131196","journal-title":"Neuro Oncol"},{"issue":"237","key":"2029_CR89","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q et al (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 6(237):237ra68. \nhttps:\/\/doi.org\/10.1126\/scitranslmed.3008639","journal-title":"Sci Transl Med."},{"issue":"1","key":"2029_CR90","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2014.04.044","volume":"134","author":"NR Shah","year":"2014","unstructured":"Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C et al (2014) Analyses of merlin\/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer. Gynecol Oncol 134(1):104\u2013111. \nhttps:\/\/doi.org\/10.1016\/j.ygyno.2014.04.044","journal-title":"Gynecol Oncol"},{"issue":"12","key":"2029_CR91","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M et al (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 27(12):2268\u20132274. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdw427","journal-title":"Ann Oncol"},{"issue":"5","key":"2029_CR92","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-016-3010-1","volume":"77","author":"T Shimizu","year":"2016","unstructured":"Shimizu T, Fukuoka K, Takeda M, Iwasa T, Yoshida T, Horobin J et al (2016) A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 77(5):997\u20131003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2029_CR93","doi-asserted-by":"crossref","first-page":"e0197350","DOI":"10.1371\/journal.pone.0197350","volume":"13","author":"R Allaway","year":"2018","unstructured":"Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M et al (2018) Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One 13(6):e0197350","journal-title":"PLoS One"},{"issue":"4","key":"2029_CR94","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2010.11.SPINE10350","volume":"14","author":"SR Plotkin","year":"2011","unstructured":"Plotkin SR, O\u2019Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP (2011) Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine. 14(4):543\u2013547","journal-title":"J Neurosurg Spine."},{"issue":"6","key":"2029_CR95","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1440-1789.2012.01306.x","volume":"32","author":"C Hagel","year":"2012","unstructured":"Hagel C, Stemmer-Rachamimov AO, Bornemann A, Schuhmann M, Nagel C, Huson S et al (2012) Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology 32(6):611\u2013616. \nhttps:\/\/doi.org\/10.1111\/j.1440-1789.2012.01306.x","journal-title":"Neuropathology"},{"issue":"3","key":"2029_CR96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11060-017-2690-7","volume":"136","author":"M Kalamarides","year":"2018","unstructured":"Kalamarides M, Essayed W, Lejeune JP, Aboukais R, Sterkers O, Bernardeschi D et al (2018) Spinal ependymomas in NF2: a surgical disease? J Neurooncol 136(3):605\u2013611","journal-title":"J Neurooncol"},{"issue":"6","key":"2029_CR97","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ane.12490","volume":"133","author":"S Farschtschi","year":"2016","unstructured":"Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR et al (2016) Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand 133(6):475\u2013480","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"2029_CR98","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/neuros\/nyx374","volume":"83","author":"AT King","year":"2018","unstructured":"King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON et al (2018) High-grade glioma is not a feature of neurofibromatosis type 2 in the unirradiated patient. Neurosurgery 83(2):193\u2013196. \nhttps:\/\/doi.org\/10.1093\/neuros\/nyx374","journal-title":"Neurosurgery"},{"issue":"392","key":"2029_CR99","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jns.2018.07.018","volume":"15","author":"C Tomkinson","year":"2018","unstructured":"Tomkinson C, Lu JQ (2018) Meningioangiomatosis: a review of the variable manifestations and complex pathophysiology. J Neurol Sci 15(392):130\u2013136. \nhttps:\/\/doi.org\/10.1016\/j.jns.2018.07.018","journal-title":"J Neurol Sci"},{"issue":"1","key":"2029_CR100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-3639.2005.tb00100.x","volume":"15","author":"A Perry","year":"2005","unstructured":"Perry A, Kurtkaya-Yapicier O, Scheithauer BW, Robinson S, Prayson RA, Kleinschmidt-DeMasters BK et al (2005) Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. Brain Pathol 15(1):55\u201365","journal-title":"Brain Pathol"},{"issue":"Pt 4","key":"2029_CR101","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/brain\/122.4.709","volume":"122","author":"S Wiebe","year":"1999","unstructured":"Wiebe S, Munoz DG, Smith S, Lee DH (1999) Meningioangiomatosis. A comprehensive analysis of clinical and laboratory features. Brain 122(Pt 4):709\u2013726","journal-title":"Brain"},{"key":"2029_CR102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1749-6632.1986.tb48058.x","volume":"486","author":"LJ Rubinstein","year":"1986","unstructured":"Rubinstein LJ (1986) The malformative central nervous system lesions in the central and peripheral forms of neurofibromatosis. A neuropathological study of 22 cases. Ann N Y Acad Sci. 486:14\u201329","journal-title":"Ann N Y Acad Sci."},{"key":"2029_CR103","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00005053-191512000-00001","volume":"42","author":"P Bassoe","year":"1912","unstructured":"Bassoe P, Nuzum F (1912) Report of a case of central and peripheral neurofibromatosis. J Nerv Ment Dis 42:785\u2013796","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"2029_CR104","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00005072-199705000-00004","volume":"56","author":"AO Stemmer-Rachamimov","year":"1997","unstructured":"Stemmer-Rachamimov AO, Horgan MA, Taratuto AL, Munoz DG, Smith TW, Frosch MP et al (1997) Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene. J Neuropathol Exp Neurol 56(5):485\u2013489","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"2029_CR105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-3639.2005.tb00100.x","volume":"15","author":"A Perry","year":"2005","unstructured":"Perry A, Kurtkaya-Yapicier O, Scheithauer BW, Robinson S, Prayson RA, Kleinschmidt-DeMasters BK et al (2005) Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. Brain Pathol 15(1):55\u201365","journal-title":"Brain Pathol"},{"issue":"6","key":"2029_CR106","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.surneu.2005.09.034","volume":"65","author":"I Omeis","year":"2006","unstructured":"Omeis I, Hillard VH, Braun A, Benzil DL, Murali R, Harter DH (2006) Meningioangiomatosis associated with neurofibromatosis: report of two cases in a single family and review of the literature. Surg Neurol 65(6):595\u2013603","journal-title":"Surg Neurol"},{"issue":"2","key":"2029_CR107","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10024-004-9105-4","volume":"8","author":"C Wixom","year":"2005","unstructured":"Wixom C, Chadwick AE, Krous HF (2005) Sudden, unexpected death associated with meningioangiomatosis: case report. Pediatr Dev Pathol 8(2):240\u2013244","journal-title":"Pediatr Dev Pathol"},{"issue":"1","key":"2029_CR108","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2990.2002.00365.x","volume":"28","author":"NR Kim","year":"2002","unstructured":"Kim NR, Choe G, Shin SH, Wang KC, Cho BK, Choi KS et al (2002) Childhood meningiomas associated with meningioangiomatosis: report of five cases and literature review. Neuropathol Appl Neurobiol 28(1):48\u201356","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"2029_CR109","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00234-013-1292-0","volume":"55","author":"TY Jeon","year":"2013","unstructured":"Jeon TY, Kim JH, Suh YL, Ahn S, Yoo SY, Eo H (2013) Sporadic meningioangiomatosis: imaging findings with histopathologic correlations in seven patients. Neuroradiology 55(12):1439\u20131446. \nhttps:\/\/doi.org\/10.1007\/s00234-013-1292-0","journal-title":"Neuroradiology"},{"key":"2029_CR110","doi-asserted-by":"publisher","first-page":"361203","DOI":"10.1155\/2011\/361203","volume":"2011","author":"ON Kashlan","year":"2011","unstructured":"Kashlan ON, Laborde DV, Davison L, Saindane AM, Brat D, Hudgins PA et al (2011) Meningioangiomatosis: a case report and literature review emphasizing diverse appearance on different imaging modalities. Case Rep Neurol Med 2011:361203. \nhttps:\/\/doi.org\/10.1155\/2011\/361203","journal-title":"Case Rep Neurol Med"},{"issue":"6","key":"2029_CR111","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1017\/cjn.2016.292","volume":"43","author":"FA Nascimento","year":"2016","unstructured":"Nascimento FA, Kiehl TR, Tai PC, Valiante TA, Krings T (2016) Meningioangiomatosis: a disease with many radiological faces. Can J Neurol Sci 43(6):847\u2013849","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"2029_CR112","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00701-003-0047-9","volume":"145","author":"Y Ohta","year":"2003","unstructured":"Ohta Y, Nariai T, Ishii K, Ishiwata K, Senda M, Okeda R et al (2003) Meningio-angiomatosis in a patient with focal epilepsy: value of PET in diagnoses and preoperative planning of surgery. Acta Neurochir (Wien) 145(7):587\u2013590 (discussion 590-1)","journal-title":"Acta Neurochir (Wien)"},{"issue":"10","key":"2029_CR113","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/jnen\/nly075","volume":"77","author":"S Rossi","year":"2018","unstructured":"Rossi S, Brenca M, Zanatta L, Trincia E, Guerriero A, Pizzato C et al (2018) A pediatric intra-axial malignant SMARCB1-deficient desmoplastic tumor arising in meningioangiomatosis. J Neuropathol Exp Neurol 77(10):883\u2013889. \nhttps:\/\/doi.org\/10.1093\/jnen\/nly075","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"2029_CR114","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00294370","volume":"79","author":"OD Wiestler","year":"1989","unstructured":"Wiestler OD, von Siebenthal K, Schmitt HP, Feiden W, Kleihues P (1989) Distribution and immunoreactivity of cerebral micro-hamartomas in bilateral acoustic neurofibromatosis (neurofibromatosis 2). Acta Neuropathol 79(2):137\u2013143","journal-title":"Acta Neuropathol"},{"issue":"4","key":"2029_CR115","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.nicl.2013.12.010","volume":"4","author":"WS Vargas","year":"2014","unstructured":"Vargas WS, Heier LA, Rodriguez F, Bergner A, Yohay K (2014) Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2. Neuroimage Clin 4(4):258\u2013265. \nhttps:\/\/doi.org\/10.1016\/j.nicl.2013.12.010","journal-title":"Neuroimage Clin"},{"issue":"6","key":"2029_CR116","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00005072-199706000-00011","volume":"56","author":"AO Stemmer-Rachamimov","year":"1997","unstructured":"Stemmer-Rachamimov AO, Gonzalez-Agosti C, Xu L, Burwick JA, Beauchamp R, Pinney D et al (1997) Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J Neuropathol Exp Neurol. 56(6):735\u2013742","journal-title":"J Neuropathol Exp Neurol."},{"issue":"5","key":"2029_CR117","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/PAS.0b013e31824d3155","volume":"36","author":"A Harder","year":"2012","unstructured":"Harder A, Wesemann M, Hagel C, Schittenhelm J, Fischer S, Tatagiba M et al (2012) Hybrid neurofibroma\/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 36(5):702\u2013709","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2029_CR118","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5414\/np300895","volume":"35","author":"BK Montgomery","year":"2016","unstructured":"Montgomery BK, Alimchandani M, Mehta GU, Dewan R, Nesvick CL, Miettinen M et al (2016) Tumors displaying hybrid schwannoma and neurofibroma features in patients with neurofibromatosis type 2. Clin Neuropathol 35(2):78\u201383. \nhttps:\/\/doi.org\/10.5414\/np300895","journal-title":"Clin Neuropathol"},{"issue":"2","key":"2029_CR119","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00401-016-1583-8","volume":"132","author":"A Schulz","year":"2016","unstructured":"Schulz A, B\u00fcttner R, Hagel C, Baader SL, Kluwe L, Salamon J et al (2016) The importance of nerve microenvironment for schwannoma development. Acta Neuropathol 132(2):289\u2013307","journal-title":"Acta Neuropathol"},{"issue":"374","key":"2029_CR120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuroscience.2018.01.054","volume":"15","author":"K Truong","year":"2018","unstructured":"Truong K, Ahmad I, Jason Clark J, Seline A, Bertroche T, Mostaert B et al (2018) Nf2 mutation in schwann cells delays functional neural recovery following injury. Neuroscience 15(374):205\u2013213","journal-title":"Neuroscience"},{"issue":"3","key":"2029_CR121","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archopht.125.3.389","volume":"125","author":"ME McLaughlin","year":"2007","unstructured":"McLaughlin ME, Pepin SM, Maccollin M, Choopong P, Lessell S (2007) Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 125(3):389\u2013394","journal-title":"Arch Ophthalmol"},{"key":"2029_CR122","first-page":"92","volume":"33","author":"VF Mautner","year":"1993","unstructured":"Mautner VF, Tatagiba M, Guthoff R, Samii M, Pulst SM (1993) Neurofibromatosis 2 in the pediatric age group. Neurosurgery 33:92\u201396","journal-title":"Neurosurgery"}],"updated-by":[{"DOI":"10.1007\/s00401-019-02044-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:00:00Z","timestamp":1566259200000}}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-019-02029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-019-02029-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-019-02029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T09:03:06Z","timestamp":1589619786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-019-02029-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1007\/s00401-019-02029-5","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article An update on the CNS manifestations of neurofibromatosis type 2, written by Shannon Coy, Rumana Rashid, Anat Stemmer\u2011Rachamimov and Sandro Santagata, was originally published electronically on the publisher\u2019s internet portal (currently SpringerLink) on 04 June 2019 without open access.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}